Research Signal – Source date 2021-03-01
About 5% of people with metastatic colorectal cancer have tumours with deficient mismatch repair, a faulty system for correcting errors made when DNA is copied. That difference matters when choosing treatment: these tumours are biologically distinct, yet patients commonly receive the same chemotherapy and monoclonal antibodies as patients whose mismatch repair works normally.
A 2021 evidence-based review asks whether those standard treatments benefit the deficient-mismatch-repair group to the same extent. Its answer is not a simple comparison of drug-by-drug results. The review brings together clinical trials and biological arguments, while identifying gaps that make treatment choices difficult to judge.
Immunotherapy leaves a consequential treatment question
Immunotherapy benefits many people with deficient-mismatch-repair metastatic colorectal cancer. But the review reports that 20–30% do not respond. For them, other systemic treatments remain important, and the choices may include chemotherapy and monoclonal antibodies—medicines designed to act on specific targets.
The review’s concern is that these conventional options are often used across both mismatch-repair groups even though the tumours differ biologically. It examines clinical trials of different chemotherapy types and monoclonal antibodies to assess their efficacy in deficient-mismatch-repair disease. The review does not establish which chemotherapy or antibody treatment works best for people in this group, including those whose cancer did not respond to immunotherapy.
The review also notes that this group has a worse prognosis than patients with proficient mismatch repair. That observation makes treatment response an important question, but it does not show that a lower response to a particular treatment caused the prognosis difference. Outcomes can’t be used on their own to determine which drug would work better or explain why the groups fare differently.
The model can shape the biological argument
To interpret why treatment might work differently, researchers also study tumour models. The review points to a limitation in the models commonly used: cell lines, which are cancer cells grown in a dish, and xenografts, in which tumour material is grown in an animal, are less representative than patient-derived organoids. Organoids are three-dimensional cell models made from a patient’s tumour tissue.
The choice of model affects how confidently a laboratory result can inform a clinical question. If a model does not closely represent the tumour and its surroundings, a proposed biological explanation for treatment response may not translate to patients. Patient-derived organoids may offer a more representative model, but the review does not establish that they predict clinical benefit.
This matters because future strategies may combine immunotherapy, chemotherapy and monoclonal antibodies. The review offers recommendations for clinical investigators and laboratory researchers, but a rationale for testing a combination is not evidence that it improves outcomes. Better models and treatment comparisons would help clarify which possibilities deserve clinical evaluation.
What better treatment matching could mean for metastatic colorectal cancer
If comparative evidence identifies systemic treatments that benefit people with deficient mismatch repair—including those who do not respond to immunotherapy—clinicians could have a firmer basis for matching treatment to tumour type. That could spare some patients exposure to drugs that are unlikely to help, along with their associated toxicity. The benefit depends on establishing which treatments work for this group; the review’s evidence does not yet settle that choice.
Key Sources
- Primary source: A review of the sensitivity of metastatic colorectal cancer patients with deficient mismatch repair to standard-of-care chemotherapy and monoclonal antibodies, with recommendations for future research.
DOI or Journal Page · Review or Meta-Analysis · 2021-03-01
Keep exploring